Medtronic stock: FDA clearance adds focus before Nov. 24 results

Medtronic stock traded at 93.61 euros on Lang & Schwarz at 5:08 p.m. CET on Friday, November 13. That was 2.16 percent above the 91.63 euros quoted in our report of November 13, giving investors a fresh market checkpoint before the company's next results.

On November 9, Medtronic announced the launch of the Aristotle Mini Guidewire after FDA clearance. The company's business and regional news page describes the device as a low-profile access technology that complements the Onyx liquid embolic system for navigation and treatment in smaller, more distal neurovascular anatomy.

Product milestone before results

The clearance expands Medtronic's neurovascular product offering in procedures involving difficult small-vessel access. The announcement establishes a product milestone, but it does not provide a sales forecast or revenue contribution for the guidewire.

Medtronic's next scheduled financial event is its fiscal second-quarter update. In its November 4 announcement, the company said it will publish results on Tuesday, November 24, 2026, for the quarter ended October 30. The financial release is scheduled for 5:45 a.m. Central Time, followed by a webcast at 6:30 a.m. Central Time.

For investors, the upcoming report will provide the next consolidated view of revenue, margins and demand after a series of portfolio updates. The key question is whether recent product and regulatory milestones are beginning to support commercial momentum across Medtronic's businesses.

Current market context is available in the Current market reports.

More news and analyses on Medtronic stock.